Start main content

Highly Effective COVID-19 Vaccine Using Linked Immunodominant Linear Peptides from SARS-CoV2

Highly Effective COVID-19 Vaccine Using Linked Immunodominant Linear Peptides from SARS-CoV2
Field
Vaccine
Patent
IP00952

Key Problem and Market Opportunity

  • The available COVID-19 vaccines may not induce neutralizing antibodies which potentially cause antibody-dependent enhancement
  • Due to recent discovery of variants of SARS-CoV2 in human samples, antigenic drift is one of the key concerns
  • Various types of vaccine in the market may not effectively fight against the variants
  • Linear peptides containing the essential immunodominant sites of SARS-CoV2 are good candidates for the next generation of the COVID vaccine

Key Advantages of the Technology

Technology Section Slider 1
Technology Section Slider 2
  • Linear polypeptides is used without cloning the whole S protein ()
  • Induces high titers of binding antibodies and cellular immune response hamster model
  • S protein-immunodominant (S-ID) induced robust neutralizing antibody response in mice
  • S-ID significantly improves disease outcome in hamsters ()
  • Application wise, these polypeptides are non-viral and easy to make. Thus, it is a very safe, new candidate for COVID-19 vaccine

Further Details

  • Published in 10, 874–884 (2021)

 

Potential Product and Services

Highly immunogenic linear peptide-based COVID-19 Vaccine

Development Status and IP Strength

Stage of Development 
  • Completed animal model study
Patents
  • PCT App. No.: PCT/CN2021/090680
IP Status
  • Patent application submitted

Work with us